Innovir Laboratories Inc., of New York, entered a collaboration with The Scripps Research Institute, of La Jolla, Calif., to evaluate in animal models a new drug candidate for chronic hepatitis B. The lead drug comes from a class of compounds developed using Innovir's site-specific External Guide Sequence technology, and will be delivered by the company's new system to facilitate entry into liver cells. * Interferon Sciences Inc., of New Brunswick, N.J., said its low-dose oral alpha interferon

The decision was based on an interim analysis of an ongoing double-blind, placebo-controlled study of 288 patients. * Innovir Laboratories Inc., of New York, entered a collaboration with The Scripps Research Institute, of La Jolla, Calif., to evaluate in animal models a new drug candidate for chronic hepatitis B. The lead drug comes from a class of compounds developed using Innovir's site-specific External Guide Sequence technology, and will be delivered by the company's new system to

Alteon Inc., of Ramsey, N.J., said it discovered a novel class of orally available compounds that lowers blood glucose and free fatty acid levels in animal models of Type II diabetes...The decision was based on an interim analysis of an ongoing double-blind, placebo-controlled study in 288 patients. * Innovir Laboratories Inc., of New York, entered a collaboration with The Scripps Research Institute, of La Jolla, Calif., to evaluate in animal models a new drug candidate for chronic hepatitis B

Underwriters are Vector Securities International Inc., of Deerfield, Ill., and J.P. Morgan & Co., of New York. * SunPharm Corp., of Jacksonville, Fla., signed an agreement with the Mayo Clinic in Jacksonville, whose researchers will test SunPharm's polyamine analogues in animal models of Alzheimer's disease progression. * Synsorb Biotech Inc., of Calgary, Alberta, began a Phase III double-blind, placebo-controlled study of Synsorb Pk, which is being developed for hemolytic uremic syndrome, or

The compound was efficacious in animal models of gingivitis. * Theratech Inc., of Salt Lake City, said its board approved a 3-for-2 stock split

The company now owns worldwide rights to the drug. * Scios Nova Inc., of Mountain View, Calif., said basic fibroblast growth factor (bFGF) reduced brain injury in experimentally induced stroke in animal models

The drug is approved in 15 European Union countries. * Scios Nova Inc., of Mountain View, Calif., said basic fibroblast growth factor (bFGF) reduced brain injury in experimentally induced stroke in animal models

Alexion Pharmaceuticals Inc., of New Haven, Conn., said its complement inhibitor monoclonal antibody was effective in two different animal models of glomerulonephritis, a form of kidney inflammation associated with lupus. * Genentech Inc., of South San Francisco, said its non- Roche shareholders approved the transaction that extends for four year's Switzerland-based Roche Holding Ltd.'s option to have Genentech redeem the outstanding stock of the company, and provides for shareholders to put

Theratechnologies estimated the market for the animal models at $30 million annually. * Vaxcel Inc., of Atlanta, a subsidiary of CytRx Corp., also in Atlanta, signed an option agreement for evaluation of its Optivax vaccine delivery system by London-based Medeva plc for use with one of its viral antigen

The sale includes eight GenPharm transgenic animal models, such as the TSG-p53 transgenic mouse, which is deficient in the p53 tumor suppressor gene. * Interneuron Pharmaceuticals Inc., of Lexington, Mass., said a double-blind, placebo-controlled study in the U.K

The sale includes eight GenPharm transgenic animal models, such as the TSG-p53 transgenic mouse, which is deficient in the p53 tumor suppressor gene. * Interneuron Pharmaceuticals Inc., of Lexington, Mass., said a double-blind, placebo-controlled study in the U.K

The move eliminated certain officer positions, including that of former president William Bliss. * U.S. Bioscience Inc., of West Conshohocken, Pa., signed an exclusive marketing and distribution agreement for Hexalen and NeuTrexin in Europe with Beaufour Ipsen, a privately held French pharmaceutical company. * Corvas International Inc., of San Diego, said data reported at a symposium in Germany showed its neutrophil inhibitory factor reduced brain injury in an animal model of stroke. * Rhone

The antisense oligonucleotide, which has shown activity against tumors in animal models, is expected to be taken into the clinic in 1996. * Alexion Pharmaceuticals Inc., of Cambridge, Mass., unveiled a new class of recombinant autoantigens, called Apogens, for the treatment of multiple sclerosis. * ImClone Systems Inc., of New York, initiated two Phase Ib/IIa trials of its lead cancer drug, C225, an epidermal growth factor receptor antagonist. * Univax Biologics Inc., of Rockville, Md., said

Efficacy studies are planned for patients with ovarian, colorectal, prostate, pancreatic and lung cancers. * ImClone Systems Inc., of New York, said preclinical studies of its anti-flk-1 monoclonal antibody, DC101, showed the drug suppressed the growth of human gliobastomal tumors in an animal model

Efficacy studies are planned for patients with ovarian, colorectal, prostate, pancreatic and lung cancers. * ImClone Systems Inc., of New York, said preclinical studies of its anti-flk-1 monoclonal antibody, DC101, showed the drug suppressed the growth of human gliobastomal tumors in an animal model

ESCAgenetics said it is considering an appeal and will seek to have its stock listed on the over-the-counter market if it is not traded on the American Stock Exchange. * Inflazyme Pharmaceuticals Ltd., of Vancouver, Canada, entered into a research collaboration with Mount Sinai Medical Center at the University of Miami to study Inflazyme's anti-asthma drug, IZP- 94005 in an animal model of asthma utilizing sheep. * Advanced Tissue Sciences Inc., of La Jolla, Calif., and U.K.-based Smith

Ltd., of Osaka, Japan, on the research and development of small molecules that act by up- regulating the low density lipoprotein receptor to lower the amount of serum cholesterol in those with hypercholesterolemia. * Genta Inc., of San Diego, said an antisense drug targeted against the BCL-2 gene was effective against drug-resistant cancerous tumors in certain animals models of follicular lymphoma and colon cancer. * CellPro Inc., of Seattle, said it started direct sales of its CEPRATE SC Stem

The company said preclinal studies of the drug showed efficacy in animal models. (c) 1997 American Health Consultants

reported positive test results of its proprietary anti-asthma drug, Pneumocort, as a topical treatment in animal models. (c) 1997 American Health Consultants